Inspire's Q1 2026 print attributes a combined $120 to $150 million FY26 hit to WISeR plus coding uncertainty, six sell-side analysts cut targets through 7 May, and NeuroPace just received a 43% to 47% Medicare reimbursement increase on the same rule cycle.
Mobia Medical, the company behind the only FDA-approved implanted vagus nerve stimulator for chronic stroke recovery, priced its $150 million IPO at $15 on 7 May 2026 and closed week one at $11.75. The print resets implied exit math for the pre-IPO bioelectronic-medicine cohort preparing 2026-27 listings.
BlueWind Medical closed $47.8 million in combined equity and debt financing on 14 May 2026 to scale US commercialisation of Revi, the only FDA-cleared implantable tibial neuromodulation device for urgency urinary incontinence. The round follows three-year OASIS pivotal trial data and Medtronic's September 2025 FDA approval of its competing Altaviva tibial system.
Imperial College London spinout MintNeuro signed a multi-year commercial supply agreement on 6 May 2026 to provide its miniaturised sensing and stimulation integrated circuits to Motif Neurotech's DOT depression implant across pre-clinical, early clinical, and pivotal trial phases. The deal lands two weeks after Motif's FDA Investigational Device Exemption clearance.
NeuroPace reported Q1 2026 RNS System revenue of $21.7 million (up 19.5% year-on-year), raised full-year guidance to $99-101 million, and detailed 18-month NAUTILUS trial data showing a 77% median reduction in generalised tonic-clonic seizures. FDA paused the 180-day clock on the expanded-indication review; midyear determination still anticipated.
Illinois Institute of Technology and Rush University Medical Center completed the third implantation of the Intracortical Visual Prosthesis on 7 May 2026, a 34-stimulator, 544-electrode wireless system bypassing the eye and optic nerve to deliver artificial sight directly to the visual cortex.
Humana issues the first Medicare Advantage coverage policy for CVRx's Barostim baroreflex neuromodulation therapy effective 1 May 2026, the fourth 2026 reimbursement and trial milestone for the bioelectronic heart-failure category.
Opie joins ASX-listed Australian assistive-tech company Control Bionics as Non-Executive Director and strategic advisor, with 1.25 million options vesting over four years pending shareholder approval at the 2026 AGM.
Columbia's Zuckerman Institute and collaborators at UCSF, NYU and Northwell Health published the first real-time human-study evidence that an auditory attention decoding BCI can isolate a single speaker in a multi-talker environment.
Get the latest BCI news, breakthroughs, and market moves delivered to your inbox.
No spam. One-click unsubscribe. We respect your privacy.